Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Novartis News

    91,855 € 0,00% +0,00 €
    18:42:41 Uhr L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 904278
    ISIN: CH0012005267
    US-Symbol: NVSEF
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 6,34
    ME4FDF

    Ad-hocs

    24.04.24 - LYNX Analysen
    Novartis: Das sollte man jetzt genauer beobachten
    Der Schweizer Pharmakonzern Novartis überzeugte am Dienstag mit über den Prognosen liegenden Ergebnissen im ersten Quartal und hob daraufhin die Gesamtjahresprognose ...  Mehr »
    15.02.23 - RealMoneyTrader
    Technical Trading: 150%-Chance mit Novartis-Call
    Novartis Call Typ: Optionsschein WKN: KG719T Hebel: 12 Laufzeit: OpenEnd Einstieg: Market Ordergültigkeit: tagesgültig Stop-Loss: 0,20 Euro Ziel: 1,50 Euro ...
    29.01.20 - GlobeNewswire
    Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
    Full year net sales for c ontinuing operations 1 up 9% (cc 2 , +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 ...
    29.01.20 - GlobeNewswire
    Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
    Der Nettoumsatz der fortzuführenden Geschäftsbereiche 1 steigt 2019 um 9% (kWk 2 , +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von ...
    06.01.20 - GlobeNewswire
    Novartis completes tender offer for all outstanding shares of The Medicines Company
    Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-​owned ...
    16.12.19 - GlobeNewswire
    Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
    Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events ...
    05.12.19 - GlobeNewswire
    Novartis tender offer for The Medicines Company commences
    Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-​owned subsidiary, Medusa Merger Corporation, a Delaware corporation ...
    24.11.19 - GlobeNewswire
    Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
    Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do ...
    15.11.19 - GlobeNewswire
    New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
    Sickle cell pain crises are unpredictable, severe events associated with life-​threatening complications 1 Adakveo reduced the annual rate of sickle cell pain crises by 45% ...
    01.11.19 - GlobeNewswire
    Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
    Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira ® * [1] ...
    30.10.19 - GlobeNewswire
    Novartis announces AVXS-101 intrathecal study update
    FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-​clinical animal study Adverse events that might be expected from ...
    22.10.19 - GlobeNewswire
    Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
    Continuing operations 2 net sales up 13% (cc 1 , +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions Entresto ...
    22.10.19 - GlobeNewswire
    Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu
    Der Nettoumsatz der fortzuführenden Geschäftsbereiche 2 steigt aufgrund folgender Beiträge um 13% (kWk 1 , +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen ...
    02.10.19 - GlobeNewswire
    Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
    Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-​radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis ...
    17.09.19 - GlobeNewswire
    Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
    Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-​radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also ...
    30.08.19 - GlobeNewswire
    Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
    In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio ®* (teriflunomide) in patients with relapsing forms of MS ...
    05.11.18 - GlobeNewswire
    Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
    Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms Novartis International AG / Novartis R&D ...
    10.10.18 - GlobeNewswire
    Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
    Novartis announces new data from the first direct head-​to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple ...
    11.09.18 - GlobeNewswire
    Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz
    Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz Novartis International AG / Alcon bestätigt vor dem vorgeschlagenen Spin-off von ...
    11.09.18 - GlobeNewswire
    Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
    Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis Novartis International AG / Alcon confirms commitment to Switzerland ahead of proposed spinoff ...
    29.08.18 - GlobeNewswire
    Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
    Alcon announces voluntary global market withdrawal of CyPass Micro-​Stent for surgical glaucoma Novartis International AG / Alcon announces voluntary global market withdrawal of ...
    27.08.18 - GlobeNewswire
    Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission
    Novartis erhält die Zulassung für seine CAR-​T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission Novartis International AG / Novartis erhält die ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »